secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001193125-25-119939
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase Q1 net loss $13.7M; advancing IKT-001 PAH Ph2b trial in H2 2025
--------------------------------------------------------------------------

- Net loss $13.7M ($0.15/share) vs $4.6M ($0.73) in Q1 2024; includes $7.4M non-cash acquisition charge for CorHepta.
- R&D expenses $10.5M (incl. $7.4M IPR&D charge); SG&A $5.2M; cash $93.2M at March 31, 2025.
- Appointed new CEO (Mark Iwicki), President/Head of R&D (Chris Cabell), CSO (John Adams), CFO (David McIntyre).
- IKT-001 Phase 2b PAH study design finalizing; trial initiation expected H2 2025; FDA 'Study May Proceed' received Sept 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312525119939/0001193125-25-119939-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312525119939/d940084d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-119939

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer